Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020
Xencor, Inc. (NASDAQ: XNCR) will announce its third quarter 2020 financial results on November 5, 2020, after market close. Management will host a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Investors can access the call via phone or through the company’s website. Xencor focuses on developing engineered monoclonal antibodies targeting cancer and autoimmune diseases, with 18 candidates currently in clinical development leveraging its proprietary XmAb® technology.
- None.
- None.
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release third quarter 2020 financial results after the market closes on Thursday, November 5, 2020.
Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers and referencing conference ID number 7307079. A live webcast of the conference call will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. The webcast will be archived on the company website for 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 18 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
